Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Internal Medicine Journal|October 28, 2024
Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in AustraliaNatasha Yap, Vanessa Wong, Catherine Morton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Samantha R Oakes, François Vaillant, Elgene Lim, et al.
Cell|September 26, 2015
CDK7-dependent transcriptional addiction in triple-negative breast cancerYubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, et al.
Nature Communications|November 21, 2015
Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlabauer, et al.
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Nature Communications|October 28, 2015
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlbauer, et al.
Cancer Cell|August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
Breast Cancer Research and Treatment|December 2, 2021
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testingPhuong Dinh, J Dinny Graham, Elisabeth N Elder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic DiseaseZahra Sabahi, Andrew Nguyen, Keith Wong, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Internal Medicine Journal|October 28, 2024
Medicine Access Programmes: what do patients think - a patient-reported outcome study on ribociclib in metastatic breast cancer in AustraliaNatasha Yap, Vanessa Wong, Catherine Morton, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Samantha R Oakes, François Vaillant, Elgene Lim, et al.
Cell|September 26, 2015
CDK7-dependent transcriptional addiction in triple-negative breast cancerYubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, et al.
Nature Communications|November 21, 2015
Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlabauer, et al.
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Nature Communications|October 28, 2015
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlbauer, et al.
Cancer Cell|August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
Breast Cancer Research and Treatment|December 2, 2021
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testingPhuong Dinh, J Dinny Graham, Elisabeth N Elder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2025
Diagnostic Potential of <sup>68</sup>Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic DiseaseZahra Sabahi, Andrew Nguyen, Keith Wong, et al.
Pageof 13